ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 26468985

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.

Baldelli E and 14 others. Oncotarget, 2015. Cited by 24 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. Papers, record 26468985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26468985

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.
PubMed
Journal
Oncotarget
PubMed
Year
2015
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
0.54
iCite
Revised in PubMed
2021-08-16
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Baldelli EElisa
2Bellezza GGuido
3Haura EBEric B
4Crinó LLucio
5Cress WDW Douglas
6Deng JJianghong
7Ludovini VVienna
8Sidoni AAngelo
9Schabath MBMatthew B
10Puma FFrancesco

1 to 10 of 15Source PubMed

See all 15 authors

Topics28

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AdenocarcinomaMajor topic
Biomarkers, TumorMajor topic
Lung NeoplasmsMajor topic
MutationMajor topic
Proto-Oncogene Proteins p21(ras)Major topic
Signal TransductionMajor topic
Adenocarcinoma of Lung
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal
DNA Mutational Analysis
Estrogen Receptor Modulators
Estrogen Receptor alpha
Female
Florida
Genetic Predisposition to Disease
Humans
Immunohistochemistry
Italy
Male
Middle Aged
Molecular Targeted Therapy
Neoplasm Staging
Phenotype
Protein Interaction Maps
Protein Kinase Inhibitors
Proteomics
Retrospective Studies

Source PubMed

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA076292NCI NIH HHSUnited StatesP30CA076292PubMed and NIHNIH RePORTER
P50 CA070907NCI NIH HHSUnited StatesP50CA070907PubMed and NIHNIH RePORTER
R25 CA174664NCI NIH HHSUnited StatesR25CA174664PubMed and NIHNIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121,258,250
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
J Thorac Oncol2011https://conductscience.org/library/papers/21258250PubMed
226,477,306Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.Oncogene2016https://conductscience.org/library/papers/26477306PubMed
324,510,676Preparation and use of reverse protein microarrays.Curr Protoc Protein Sci2014https://conductscience.org/library/papers/24510676PubMed
425,323,927Drugging the undruggable RAS: Mission possible?Nat Rev Drug Discov2014https://conductscience.org/library/papers/25323927PubMed
524,889,603In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.Proc Natl Acad Sci U S A2014https://conductscience.org/library/papers/24889603PubMed
622,081,344Antibody validation by Western blotting.Methods Mol Biol2012https://conductscience.org/library/papers/22081344PubMed
717,406,286Laser-capture microdissection.Nat Protoc2006https://conductscience.org/library/papers/17406286PubMed
821,124,782Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.PLoS One2010https://conductscience.org/library/papers/21124782PubMed
924,346,432Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations.Cancer Res2014https://conductscience.org/library/papers/24346432PubMed
1011,929,836Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen.Cancer Res2002https://conductscience.org/library/papers/11929836PubMed

1 to 10 of 49

See all 49 references

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
41,712,875Current Insights and Future Directions of Multiomic and Spatial-Omic Analysis in Non-Small Cell Lung Cancer.JCO Precis Oncol2026https://conductscience.org/library/papers/41712875PubMed
40,849,356Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies.Br J Cancer2025https://conductscience.org/library/papers/40849356PubMed
38,254,014Mapping three-dimensional intratumor proteomic heterogeneity in uterine serous carcinoma by multiregion microsampling.Clin Proteomics2024https://conductscience.org/library/papers/38254014PubMed
38,113,333RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling.Sci Signal2023https://conductscience.org/library/papers/38113333PubMed
35,944,066Functional and biological heterogeneity of KRASQ61 mutations.Sci Signal2022https://conductscience.org/library/papers/35944066PubMed
34,620,701PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine.J Immunother Cancer2021https://conductscience.org/library/papers/34620701PubMed
34,278,265Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens.iScience2021https://conductscience.org/library/papers/34278265PubMed
34,154,611Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN.J Exp Clin Cancer Res2021https://conductscience.org/library/papers/34154611PubMed
33,802,212Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models.Int J Mol Sci2021https://conductscience.org/library/papers/33802212PubMed
33,722,854The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy.Mol Cancer Ther2021https://conductscience.org/library/papers/33722854PubMed

1 to 10 of 19

See all 19 cited by

Genes32

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABL125PubTator's text mininghttps://conductscience.org/library/genes/25NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CYP19A11,588PubTator's text mininghttps://conductscience.org/library/genes/1588NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EIF2A83,939PubTator's text mininghttps://conductscience.org/library/genes/83939NCBI Gene
ELK12,002PubTator's text mininghttps://conductscience.org/library/genes/2002NCBI Gene
EPHB22,048PubTator's text mininghttps://conductscience.org/library/genes/2048NCBI Gene
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ERBB32,065PubTator's text mininghttps://conductscience.org/library/genes/2065NCBI Gene

1 to 10 of 32

See all 32 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26468985

GET https://conductscience.org/api/papers/v1/26468985/references?page=2

API referenceFor AI assistants